Journal of Microbiology and Biotechnology

  • 제16권12호
  • /
  • Pages.1919-1927
  • /
  • 2006
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지

MethA Fibrosarcoma Cells Expressing Membrane-Bound Forms of IL-2 Enhance Antitumor Immunity

  • Sonn, Chung-Hee (Department of Biochemistry, College of Natural Sciences, Chungnam National University) ;
  • Yoon, Hee-Ryung (Department of Biochemistry, College of Natural Sciences, Chungnam National University) ;
  • Seong, In-Ock (Department of Biochemistry, College of Natural Sciences, Chungnam National University) ;
  • Chang, Mi-Ra (Department of Biochemistry, College of Natural Sciences, Chungnam National University) ;
  • Kim, Yong-Chan (Department of Biochemistry, College of Natural Sciences, Chungnam National University) ;
  • Kang, Han-Chul (Transgene Expression Team, National Institute of Agricultural Biotechnology, Rural Development Administration) ;
  • Suh, Seok-Cheol (Transgene Expression Team, National Institute of Agricultural Biotechnology, Rural Development Administration) ;
  • Kim, Young-Sang (Department of Biochemistry, College of Natural Sciences, Chungnam National University)
  • 발행 : 2006.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tumor cells genetically engineered to secrete cytokines are effective in tumor therapy, but various unexpected side effects are observed, which may result from the bulk activation of various bystander cells. In this study, we tested tumor vaccines expressing various membrane-bound forms of IL-2 (mbIL-2) on MethA fibrosarcoma cells to focus antitumor immune responses to CTL. Chimeric forms of IL-2 with whole CD4, deletion forms of CD4, and TNF were expressed on the tumor cell surface, respectively. Tumor clones expressing mbIL-2 or secretory form of IL-2 were able to support the cell growth of CTLL-2, an IL-2-dependent T cell line, and the proliferation of spleen cells from 2C TCR transgenic mice that are responsive to the $p2Ca/L^d$ MHC class I complex. Expression of mbIL-2 on tumor cells reduced the tumorigenicity of tumor cells, and the mice that once rejected the live IL-2/TNF tumor clone acquired systemic immunity against wild-type MethA cells. The IL-2/TNF clone was inferior to other clones in tumor formation, and superior in the stimulation of the CD8+ T cell population in vitro. These results suggest that the IL-2/TNF clone is the best tumor vaccine, and may stimulate CD8+ T cells by direct priming. Expression of IL-2/TNF on tumor cells may serve as an effective gene therapy method to ameliorate the side effects encountered in the recombinant cytokine therapy and the conventional cytokine gene therapy using the secretory form of IL-2.

키워드

참고문헌

  1. Assenmacher, M., A. Scheffold, J. Schmitz, J. A. Segura Checa, S. Miltenyi, and A. Radbruch. 1996. Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man. Eur. J. Immunol. 26: 263-267 https://doi.org/10.1002/eji.1830260141
  2. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105- 2116 https://doi.org/10.1200/JCO.1999.17.7.2105
  3. Bai, X. F., J. Bender, J. Liu, H. Zhang, Y. Wang, O. Li, P. Du, P. Zheng, and Y. Liu. 2001. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J. Immunol. 167: 3936-3943 https://doi.org/10.4049/jimmunol.167.7.3936
  4. Baskar, S., N. Nabavi, L. H. Glimcher, and S. Ostrand-Rosenberg. 1993. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. Immunother. 14: 209- 215 https://doi.org/10.1097/00002371-199310000-00007
  5. Blankenstein, T., D. A. Rowley, and H. Schreiber. 1991. Cytokines and cancer: Experimental systems. Curr. Opin. Immunol. 3: 694-698 https://doi.org/10.1016/0952-7915(91)90098-L
  6. Browning, J. L., A. Ngam-ek, P. Lawton, J. DeMarinis, R. Tizard, E. P. Chow, C. Hession, B. O'Brine-Greco, S. F. Foley, and C. F. Ware. 1993. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72: 847-856 https://doi.org/10.1016/0092-8674(93)90574-A
  7. Chang, M. R., W. H. Lee, J. W. Choi, S. O. Park, S. G. Paik, and Y. S. Kim. 2005. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2. Exp. Mol. Med. 37: 240-249 https://doi.org/10.1038/emm.2005.32
  8. Chen, B., T. M. Timiryasova, D. S. Gridley, M. L. Andres, R. Dutta-Roy, and I. Fodor. 2001. Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine 15: 305-314 https://doi.org/10.1006/cyto.2001.0906
  9. Chen, K., S. Braun, S. Lyman, Y. Fan, C. M. Traycoff, E. A. Wiebke, J. Gaddy, G. Sledge, H. E. Broxmeyer, and K. Cornetta. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57: 3511-3516
  10. Cimino, A. M., P. Palaniswami, A. C. Kim, and P. Selvaraj. 2004. Cancer vaccine development: Protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol. Res. 29: 231-240 https://doi.org/10.1385/IR:29:1-3:231
  11. Colombo, M. P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte crosstalk. Cancer Res. 52: 4853-4857
  12. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543
  13. Dranoff, G. and R. C. Mulligan. 1995. Gene transfer as cancer therapy. Adv. Immunol. 58: 417-454 https://doi.org/10.1016/S0065-2776(08)60624-0
  14. el-Shami, K. M., E. Tzehoval, E. Vadai, M. Feldman, and L. Eisenbach. 1999. Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. J. Interferon Cytokine Res. 19: 1391-1401 https://doi.org/10.1089/107999099312858
  15. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403 https://doi.org/10.1016/0092-8674(90)90591-2
  16. Gabrilovich, D. I., I. F. Ciernik, and D. P. Carbone. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170: 101-110 https://doi.org/10.1006/cimm.1996.0139
  17. Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224 https://doi.org/10.1084/jem.172.4.1217
  18. Hillman, G. G., P. Slos, Y. Wang, J. L. Wright, A. Layer, M. De Meyer, M. Yudelev, M. Che, and J. D. Forman. 2004. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Ther. 11: 61-72 https://doi.org/10.1038/sj.cgt.7700656
  19. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrowderived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965 https://doi.org/10.1126/science.7513904
  20. Jackaman, C., C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. Robinson, and D. J. Nelson. 2003. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumorassociated vasculature: A novel mechanism for IL-2. J. Immunol. 171: 5051-5063 https://doi.org/10.4049/jimmunol.171.10.5051
  21. Kammula, U. S., D. E. White, and S. A. Rosenberg. 1998. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83: 797-805 https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M
  22. Kim, E. J., D. J. Kim, H. Y. Hwang, J. S. Yoon, Y. Yoon, and K. H. Baek. 2004. High-level expression of recombinant human interleukin-2 in Chinese hamster ovary cells using the expression system containing transcription terminator. J. Microbiol. Biotechnol. 14: 810-815
  23. Kim, H. Y., J. O. Yang, and G. O. Ji. 2005. Effect of bifidobacteria on production of allergy-related cytokines from mouse spleen cells. J. Microbiol. Biotechnol. 15: 265- 268 https://doi.org/10.1159/000090402
  24. Kim, Y. S., C. H. Sonn, S. G. Paik, and A. L. Bothwell. 2000. Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity. Gene Ther. 7: 837-843 https://doi.org/10.1038/sj.gt.3301175
  25. Kriegler, M., C. Perez, K. DeFay, I. Albert, and S. D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45-53 https://doi.org/10.1016/0092-8674(88)90486-2
  26. Kundig, T. M., M. F. Bachmann, C. DiPaolo, J. J. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, et al. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268: 1343-1347 https://doi.org/10.1126/science.7761853
  27. Kurt-Jones, E. A., W. Fiers, and J. S. Pober. 1987. Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts. J. Immunol. 139: 2317-2324
  28. Leonard, J. P., M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548
  29. Lollini, P. L. and G. Forni. 2003. Cancer immunoprevention: Tracking down persistent tumor antigens. Trends Immunol. 24: 62-66 https://doi.org/10.1016/S1471-4906(02)00030-3
  30. Lotze, M. T., Y. L. Matory, A. A. Rayner, S. E. Ettinghausen, J. T. Vetto, C. A. Seipp, and S. A. Rosenberg. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764-2772 https://doi.org/10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z
  31. Lu, X., N. L. Kallinteris, J. Li, S. Wu, Y. Li, Z. Jiang, G. G. Hillman, J. V. Gulfo, R. E. Humphreys, and M. Xu. 2003. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol. Immunother. 52: 592-598 https://doi.org/10.1007/s00262-003-0404-9
  32. Luo, L., A. I. Chapoval, D. B. Flies, G. Zhu, F. Hirano, S. Wang, J. S. Lau, H. Dong, K. Tamada, A. S. Flies, Y. Liu, and L. Chen. 2004. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J. Immunol. 173: 5445-5450 https://doi.org/10.4049/jimmunol.173.9.5445
  33. Marr, R. A., C. L. Addison, D. Snider, W. J. Muller, J. Gauldie, and F. L. Graham. 1997. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. 4: 1181-1188 https://doi.org/10.1038/sj.gt.3300528
  34. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumorbearing mice. Science 258: 1795-1798 https://doi.org/10.1126/science.1465616
  35. Nanni, P., G. Forni, and P. L. Lollini. 1999. Cytokine gene therapy: Hopes and pitfalls. Ann. Oncol. 10: 261-266
  36. Nizard, P., D. A. Gross, A. Babon, A. Chenal, B. Beaumelle, K. Kosmatopoulos, and D. Gillet. 2003. Anchoring cytokines MEMBRANE-BOUND FORMS OF IL-2 FOR TUMOR THERAPY 1927 to tumor cells for the preparation of anticancer vaccines without gene transfection in mice. J. Immunother. 26: 63- 71 https://doi.org/10.1097/00002371-200301000-00007
  37. Rivoltini, L., C. Gambacorti-Passerini, M. Squadrelli-Saraceno, M. I. Grosso, G. Cantu, R. Molinari, A. Orazi, and G. Parmiani. 1990. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 50: 5551-5557
  38. Salvadori, S., B. Gansbacher, A. M. Pizzimenti, and K. S. Zier. 1994. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2- secreting tumors. J. Immunol. 153: 5176-5182
  39. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335: 271-274 https://doi.org/10.1038/335271a0
  40. Soo, H. W., K. A. Lundeen, J. R. Kohrumel, N. L. Pham, S. W. Brostoff, R. M. Bartholomew, and D. J. Carlo. 1999. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J. Immunol. 162: 7343-7349
  41. Tepper, R. I. and J. J. Mule. 1994. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5: 153-164 https://doi.org/10.1089/hum.1994.5.2-153
  42. Tjuvajev, J., B. Gansbacher, R. Desai, B. Beattie, M. Kaplitt, C. Matei, J. Koutcher, E. Gilboa, and R. Blasberg. 1995. RG- 2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55: 1902-1910
  43. Townsend, S. E. and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370 https://doi.org/10.1126/science.7678351
  44. Udaka, K., T. J. Tsomides, and H. N. Eisen. 1992. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69: 989-998 https://doi.org/10.1016/0092-8674(92)90617-L
  45. Vesosky, B. and A. A. Hurwitz. 2003. Modulation of costimulation to enhance tumor immunity. Cancer Immunol. Immunother. 52: 663-669 https://doi.org/10.1007/s00262-003-0424-5
  46. Wang, Y. C., L. Zhu, R. McHugh, K. W. Sell, and P. Selvaraj. 1995. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice. Eur. J. Immunol. 25: 1163-1167 https://doi.org/10.1002/eji.1830250505
  47. Wolkers, M. C., G. Stoetter, F. A. Vyth-Dreese, and T. N. Schumacher. 2001. Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. J. Immunol. 167: 3577-3584 https://doi.org/10.4049/jimmunol.167.7.3577
  48. Yang, J. C., L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, S. M. Steinberg, H. X. Chen, and S. A. Rosenberg. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349: 427-434 https://doi.org/10.1056/NEJMoa021491
  49. Yei, S., R. M. Bartholomew, P. Pezzoli, A. Gutierrez, E. Gouveia, D. Bassett, W. Soo Hoo, and D. J. Carlo. 2002. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: Generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Gene Ther. 9: 1302-1311 https://doi.org/10.1038/sj.gt.3301803
  50. Zier, K., B. Gansbacher, and S. Salvadori. 1996. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy. Immunol. Today 17: 39- 45 https://doi.org/10.1016/0167-5699(96)80567-6